Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor

May 11, 2011 By Bio-Medicine.Org

EXTON, Pa., May 11, 2011 /PRNewswire/ — ViroPharma Incorporated
(Nasdaq:
VPHM) and Halozyme Therapeutics (Nasdaq: HALO)announced today
that Halozyme has granted ViroPharma an exclusive worldwide license
to use Halozyme’s proprietary Enhanze™ technology, a
proprietary drug delivery platform using Halozyme’s recombinant
human hyaluronidase enzyme (rHuPH20) technology in combination with
a C1 esterase inhibitor. Additionally, Halozyme has agreed not
to grant to any third party rights to use rHuPH20 to develop a
combination product for the prevention or treatment of hereditary
angioedema (HAE), or for three additional orphan disease
indications.

ViroPharma intends to apply rHuPH20 initially to develop a novel
subcutaneous formulation of Cinryze® (C1 esterase inhibitor
[human]) for routine prophylaxis against attacks of HAE. ViroPharma
seeks to combine Cinryze with rHuPH20 to enhance volume independent
biodistribution, and to increase the overall convenience of the
therapy by allowing for a single subcutaneous injection of Cinryze.
Recently completed preclinical studies have demonstrated that
rHuPH20 and Cinryze can be formulated together without compromising
the activity of either agent.  ViroPharma intends to initiate
Phase 2 clinical testing of the combination in the second half of
2011.

Halozyme’s proprietary rHuPH20 enzyme facilitates the absorption
and dispersion of drugs or fluids that are injected under the skin.
When injected under the skin, rHuPH20 transiently generates
channels in tissues underlying the outer layers of the skin to
increase the absorption and spread of injected drugs. Halozyme
maintains a patent portfolio pertaining to recombinant human
hyaluronidase which expires in 2027 in the U.S. and has additional
patent applications that relate to recombinant human hyaluronidase
and methods of using and manufacturing the enzyme that rep

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech